MNPR PE Ratio & Valuation,Is MNPR Overvalued

MNPR Relative Valuation

MNPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MNPR is overvalued; if below, it's undervalued.

Historical Valuation

Monopar Therapeutics Inc (MNPR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.31. The fair price of Monopar Therapeutics Inc (MNPR) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：74.53

Fair

-25.13

0.00

EV/EBITDA

Monopar Therapeutics Inc. (MNPR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-11.82

EV/EBIT

Monopar Therapeutics Inc. (MNPR) has a current EV/EBIT of -11.82. The 5-year average EV/EBIT is -3.83. The thresholds are as follows: Strongly Undervalued below -14.01, Undervalued between -14.01 and -8.92, Fairly Valued between 1.26 and -8.92, Overvalued between 1.26 and 6.36, and Strongly Overvalued above 6.36. The current Forward EV/EBIT of -11.82 falls within the Undervalued range.

0.00

Monopar Therapeutics Inc. (MNPR) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-13.88

P/OCF

Monopar Therapeutics Inc. (MNPR) has a current P/OCF of -13.88. The 5-year average P/OCF is -3.52. The thresholds are as follows: Strongly Undervalued below -16.74, Undervalued between -16.74 and -10.13, Fairly Valued between 3.10 and -10.13, Overvalued between 3.10 and 9.71, and Strongly Overvalued above 9.71. The current Forward P/OCF of -13.88 falls within the Undervalued range.

-39.13

P/FCF

Monopar Therapeutics Inc. (MNPR) has a current P/FCF of -39.13. The 5-year average P/FCF is -5.42. The thresholds are as follows: Strongly Undervalued below -26.53, Undervalued between -26.53 and -15.98, Fairly Valued between 5.13 and -15.98, Overvalued between 5.13 and 15.69, and Strongly Overvalued above 15.69. The current Forward P/FCF of -39.13 falls within the Strongly Undervalued range.

Monopar Therapeutics Inc (MNPR) has a current Price-to-Book (P/B) ratio of 3.52. Compared to its 3-year average P/B ratio of 5.03 , the current P/B ratio is approximately -29.98% higher. Relative to its 5-year average P/B ratio of 4.09, the current P/B ratio is about -13.92% higher. Monopar Therapeutics Inc (MNPR) has a Forward Free Cash Flow (FCF) yield of approximately -2.17%. Compared to its 3-year average FCF yield of -46.28%, the current FCF yield is approximately -95.31% lower. Relative to its 5-year average FCF yield of -34.55% , the current FCF yield is about -93.71% lower.

3.52

P/B

Median3y

5.03

Median5y

4.09

-2.17

FCF Yield

Median3y

-46.28

Median5y

-34.55

Competitors Valuation Multiple

The average P/S ratio for MNPR's competitors is 18.43, providing a benchmark for relative valuation. Monopar Therapeutics Inc Corp (MNPR) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MNPR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MNPR in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Monopar Therapeutics Inc (MNPR) currently overvalued or undervalued?

What is Monopar Therapeutics Inc (MNPR) fair value?

MNPR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Monopar Therapeutics Inc (MNPR) is between to according to relative valuation methord.

How does MNPR's valuation metrics compare to the industry average?

The average P/S ratio for MNPR's competitors is 18.43, providing a benchmark for relative valuation. Monopar Therapeutics Inc Corp (MNPR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Monopar Therapeutics Inc (MNPR) as of Dec 15 2025?

As of Dec 15 2025, Monopar Therapeutics Inc (MNPR) has a P/B ratio of 3.52. This indicates that the market values MNPR at 3.52 times its book value.

What is the current FCF Yield for Monopar Therapeutics Inc (MNPR) as of Dec 15 2025?

As of Dec 15 2025, Monopar Therapeutics Inc (MNPR) has a FCF Yield of -2.17%. This means that for every dollar of Monopar Therapeutics Inc’s market capitalization, the company generates -2.17 cents in free cash flow.

What is the current Forward P/E ratio for Monopar Therapeutics Inc (MNPR) as of Dec 15 2025?

As of Dec 15 2025, Monopar Therapeutics Inc (MNPR) has a Forward P/E ratio of -25.13. This means the market is willing to pay $-25.13 for every dollar of Monopar Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Monopar Therapeutics Inc (MNPR) as of Dec 15 2025?

As of Dec 15 2025, Monopar Therapeutics Inc (MNPR) has a Forward P/S ratio of 0.00. This means the market is valuing MNPR at $0.00 for every dollar of expected revenue over the next 12 months.

MNPR Valuation